Aytu BioScience
Specialty healthcare company focused on developing treatments for urological and related conditions.
Launch date
Employees
Market cap
€14.0m
Enterprise valuation
€11m (Public information from Sep 2024)
Share price
$2.4 AYTU
Englewood Colorado (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 7.3m | 27.6m | 65.6m | 96.7m | 107m | 81.3m | 78.2m |
| % growth | 100 % | 277 % | 138 % | 47 % | 11 % | (24 %) | (4 %) |
| EBITDA | (14.1m) | (24.6m) | (14.5m) | 41.3m | (7.6m) | - | - |
| % EBITDA margin | (193 %) | (89 %) | (22 %) | 43 % | (7 %) | - | - |
| Profit | (27.1m) | (13.6m) | (58.3m) | (110m) | (17.1m) | - | - |
| % profit margin | (371 %) | (49 %) | (89 %) | (114 %) | (16 %) | - | - |
| R&D budget | <1m | 1.7m | 5.6m | 14.4m | 4.1m | - | - |
| R&D % of revenue | 8 % | 6 % | 9 % | 15 % | 4 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $5.2m | Debt | |
| N/A | $11.8m | Post IPO Equity | |
$15.0m | Post IPO Debt | ||
* | N/A | $10.0m | Post IPO Equity |
* | $4.0m | Post IPO Equity | |
* | N/A | $3.5m | Post IPO Debt |
| Total Funding | - | ||
